Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,133.10 | 6.20 | 0.08% |
CAC 40 | 7,807.00 | 69.36 | -0.88% |
DAX 40 | 22,186.10 | 353.88 | -1.57% |
Dow JONES (US) | 41,989.96 | 11.80 | -0.03% |
FTSE 100 | 8,577.22 | 57.58 | -0.67% |
HKSE | 23,202.53 | 4.31 | -0.02% |
NASDAQ | 17,449.89 | 150.60 | 0.87% |
Nikkei 225 | 35,725.87 | 101.39 | 0.28% |
NZX 50 Index | 12,320.19 | 7.59 | 0.06% |
S&P 500 | 5,633.07 | 0.00 | 0.00% |
S&P/ASX 200 | 7,934.50 | 9.30 | 0.12% |
SSE Composite Index | 3,350.13 | 1.69 | 0.05% |